GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study

Circ Heart Fail. 2014 Jul;7(4):673-9. doi: 10.1161/CIRCHEARTFAILURE.114.000346.

¹ From the Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.B.M., T.P.C.); Duke Clinical Research Institute, Durham, NC (K.J.A., A.F.H.); Mayo Clinic, Rochester, MN (M.M.R.); Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (M.R.S.); and Harvard Medical School, Boston, MA (E.B.). ken.margulies@uphs.upenn.edu thomas.cappola@uphs.upenn.edu.
² From the Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.B.M., T.P.C.); Duke Clinical Research Institute, Durham, NC (K.J.A., A.F.H.); Mayo Clinic, Rochester, MN (M.M.R.); Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (M.R.S.); and Harvard Medical School, Boston, MA (E.B.).

No abstract available

Keywords: clinical trial; glucagon-like peptide-1; heart failure; insulin resistance.

Publication types